Published in JAMA Ophthalmol on February 01, 2013
The READ-2 Study: Ranibizumab for Edema of the mAcula in Diabetes | NCT00407381
Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. Biomed Res Int (2015) 1.54
Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study. PLoS One (2015) 1.46
Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab (2013) 1.34
Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol (2013) 1.23
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99
Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis. PLoS One (2014) 0.93
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol (2015) 0.91
Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye (Lond) (2013) 0.84
Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon? Indian J Ophthalmol (2016) 0.82
Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond) (2015) 0.81
Ranibizumab for the treatment of degenerative ocular conditions. Clin Ophthalmol (2014) 0.80
Evolving strategies in the management of diabetic retinopathy. Middle East Afr J Ophthalmol (2013) 0.80
Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation. Ther Clin Risk Manag (2016) 0.80
Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. PLoS One (2014) 0.80
Optical coherence tomography-guided selective focal laser photocoagulation: a novel laser protocol for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol (2014) 0.79
Optimal treatment of diabetic retinopathy. Ther Adv Endocrinol Metab (2013) 0.78
Functional Deficits Precede Structural Lesions in Mice With High-Fat Diet-Induced Diabetic Retinopathy. Diabetes (2016) 0.78
Anti-VEGF Therapy and the Retina: An Update. J Ophthalmol (2015) 0.78
Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). Eye (Lond) (2015) 0.78
Updates on the Clinical Trials in Diabetic Macular Edema. Middle East Afr J Ophthalmol (2016) 0.77
Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation. Jpn J Ophthalmol (2016) 0.77
Updates in the management of diabetic macular edema. J Diabetes Res (2015) 0.77
Trends in the Care of Diabetic Macular Edema: Analysis of a National Cohort. PLoS One (2016) 0.77
Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.76
Diabetic Retinopathy and Diabetic Macular Edema. Dev Ophthalmol (2015) 0.75
The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes (2015) 0.75
Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. Sci Transl Med (2017) 0.75
Multicolor pattern scan laser for diabetic retinopathy with cataract. Int J Ophthalmol (2014) 0.75
Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. Diabetes Metab Syndr Obes (2015) 0.75
Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents. J Ophthalmol (2016) 0.75
Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery. Clin Ophthalmol (2013) 0.75
Advances in drug delivery to the posterior segment. Curr Opin Ophthalmol (2015) 0.75
Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review. J Ophthalmol (2017) 0.75
Visual outcome of laser treatment in diabetic macular edema: Study from an Urban Diabetes Care Center. Pak J Med Sci (2016) 0.75
A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmol Ther (2017) 0.75
Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor. Jpn J Ophthalmol (2015) 0.75
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.60
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2010) 3.49
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res (2003) 3.34
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2009) 2.77
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology (2011) 2.65
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther (2008) 2.59
Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A (2006) 2.57
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol (2006) 2.50
Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology (2012) 2.36
Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci (2002) 2.03
Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol (2007) 2.00
Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology (2012) 1.95
MicroRNAs regulate ocular neovascularization. Mol Ther (2008) 1.89
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect (2013) 1.85
Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J Cell Physiol (2005) 1.73
VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol (2003) 1.71
Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol (2002) 1.59
AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.58
Encephalitis and myelitis associated with dengue viral infection clinical and neuroimaging features. Clin Neurol Neurosurg (2008) 1.53
Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol (2002) 1.50
The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J (2007) 1.49
Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. Retina (2003) 1.46
Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. J Neurosci (2003) 1.44
Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem (2004) 1.41
In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. Invest Ophthalmol Vis Sci (2007) 1.40
Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. Mol Ther (2009) 1.37
Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol (2002) 1.36
Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J (2006) 1.35
Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. J Biol Chem (2007) 1.34
Identification of gene expression changes associated with the progression of retinal degeneration in the rd1 mouse. Invest Ophthalmol Vis Sci (2004) 1.33
Effects of different types of oxidative stress in RPE cells. J Cell Physiol (2006) 1.32
NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. J Neurochem (2009) 1.32
Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J (2010) 1.31
A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet (2013) 1.29
Oxidative stress promotes ocular neovascularization. J Cell Physiol (2009) 1.28
Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol (2006) 1.28
Superoxide dismutase 1 protects retinal cells from oxidative damage. J Cell Physiol (2006) 1.27
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol (2004) 1.26
Combined phacoemulsification, intraocular lens implantation, and vitrectomy for eyes with coexisting cataract and vitreoretinal pathology. Am J Ophthalmol (2003) 1.26
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2006) 1.23
Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci (2004) 1.20
Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci (2002) 1.20
Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol (2004) 1.19
Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology (2013) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Retinal degeneration from oxidative damage. Free Radic Biol Med (2005) 1.17
Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci (2003) 1.16
Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci (2002) 1.16
Increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage. Antioxid Redox Signal (2009) 1.15
Use of smokeless tobacco among groups of Pakistani medical students - a cross sectional study. BMC Public Health (2007) 1.15
Overexpression of SOD in retina: need for increase in H2O2-detoxifying enzyme in same cellular compartment. Free Radic Biol Med (2011) 1.14
Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology (2010) 1.13
A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology (2009) 1.13
Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology (2009) 1.12
Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J (2005) 1.12
Gene expression variation in the adult human retina. Hum Mol Genet (2003) 1.12
Identification of novel genes preferentially expressed in the retina using a custom human retina cDNA microarray. Invest Ophthalmol Vis Sci (2003) 1.11
ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol (2009) 1.09
Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol (2012) 1.08
Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol (2003) 1.08
Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization. Invest Ophthalmol Vis Sci (2008) 1.06
Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol (2008) 1.06
Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology (2010) 1.06
Blockade of neuronal nitric oxide synthase reduces cone cell death in a model of retinitis pigmentosa. Free Radic Biol Med (2008) 1.06
Ocular gene transfer with self-complementary AAV vectors. Invest Ophthalmol Vis Sci (2007) 1.04
TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol (2006) 1.04
Minimally invasive spigelian hernia repair. JSLS (2009) 1.04
Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci (2002) 1.04
Use of colour Doppler imaging in ocular blood flow research. Acta Ophthalmol (2011) 1.04
In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res (2003) 1.04
Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol (2008) 1.04
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology (2009) 1.03
Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol (2006) 1.03
Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity. Middle East Afr J Ophthalmol (2010) 1.03
Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol (2002) 1.03
Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol (2004) 1.02
Retinal optical coherence tomography manifestations of intraocular lymphoma. J Ophthalmic Inflamm Infect (2012) 1.01
Changing patterns and outcome of Dengue infection; report from a tertiary care hospital in Pakistan. J Pak Med Assoc (2008) 1.01
Knowledge, perceptions and myths regarding infertility among selected adult population in Pakistan: a cross-sectional study. BMC Public Health (2011) 1.00
Injury-independent induction of reactive gliosis in retina by loss of function of the LIM homeodomain transcription factor Lhx2. Proc Natl Acad Sci U S A (2012) 1.00
The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci (2006) 1.00
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest (2014) 0.99
N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. J Cell Physiol (2011) 0.99
Management of retained subretinal perfluorocarbon liquid. Ophthalmic Surg Lasers Imaging Retina (2013) 0.99
Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol (2009) 0.98
Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther (2003) 0.97
Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol (2009) 0.97